In 2024,Grand Pharma strategically controls Duoputai Pharmaceutical Technology, strengthening the strategic plan in field of cerebro-cardiovascular disease treatment.
In 2023, Grand Pharma strategically acquires Tianjin Tanabe, which is a significant deployment in the field of cerebro-cardiovascular emergency.
In 2022, Grand Pharma acquired Hubei Bafeng Pharmaceutical Chemical Co., Ltd.
In 2022, a world-class R&D platform for interventional oncology and radionuclide drug conjugates (RDC) jointly built by Sirtex Medical Pty Limited (Sirtex), Telix Pharmaceutical Limited (Telix) and ITM Isotope Iechnologies Muncich SE (ITM).
In 2021, Grand Pharma acquired Cangzhou Brilliance Biotechnology Co., Ltd., accelerating the development of amino acid globalization industry.
In 2021, Grand Pharma fully acquired Jiangsu Shenming Medical Technology Co., Ltd.
In 2020, Nanjing Aoluo Biotechnology Co., Ltd. was jointly established by Grand Pharma and eTheRNA Immunotherapies NV in Belgium.
In 2020, Grand Pharma acquired a controlling stake in OncoSec, a NASDAQ-listed company in the United States, to acquire TAVO, the world's first tumour immunotherapy product.
In 2018, with CDH Investment, Grand Pharma spent nearly 10 billion to acquire 100% equity in Sirtex Medical (Sirtex), Australia‘s pharmaceutical-listed company, whose core product is [90Y] resin microspheres for the treatment of liver cancer, entering the field of oncology interventional therapy.
In 2018, Grand Pharma completed the acquisition of Shanghai Xudong Haipu Pharmaceutical Co., Ltd.
In 2017, Grand Pharma invested in and cooperated with Canadian CONAVI.
In 2016, Grand Pharma completed the acquisition of Xi'an Beilin Pharmaceutical Co., Ltd.
In 2015, Grand Pharma entered the field of cardiovascular interventions with the wholly-owned acquisition of Cardionovum of Germany, whose core products are drug-coated balloon device products
In 2015, Grand Pharma completed the acquisition of Beijing Jiuhe Pharmaceutical Co., Ltd.
In 2014, Grand Pharma acquired Tianjin Jingming New Technology Development Co., Ltd.
In July 2013, Grand Pharma acquired Beijing Huajin Pharmaceutical Co., Ltd.
In 2013, a joint venture was established with Huangshi Feiyun Pharmaceutical Co., Ltd.
In November 2012, Grand Pharma acquired Hubei Shubang Pharmaceutical Co., Ltd.
In September 2011, Grand Pharma acquired Wuhan Corona Biotechnology Co., Ltd.
In June 2010, Grand Pharma acquired Hubei Yuanda Fuchi Pharmaceutical Chemical Co., Ltd.
In 2010, Grand Pharma acquired Hubei Ruizhu Pharmaceutical Co., Ltd.
In 2008, Grand Pharma completed the acquisition of Wuhan Grand Hoyo Co., Ltd.
